CStone Starts Pivotal China Phase II Trial of PD-L1 Candidate

CStone Pharma of Suzhou has begun pivotal Phase II studies of its lead drug, a PD-L1 antibody, in two rare forms of lymphoma: natural killer cell/T-cell lymphoma and classical Hodgkin's lymphoma. The two trials will test for efficacy and safety. According to CStone, CS1001 is China 's first fully human, full-length, IgG4 based anti-PD-L1 monoclonal antibody, an IO drug that was independently developed by CStone. The first patients have been dosed the two trials. More details.... Share this with colleagues: // //